Xylem announces it has authorized a $1.5 billion share repurchase program, according to two outlets. The company frames the move as a capital allocation action, with the program size reported consistently across coverage.
Both articles describe the same core development and present the authorization amount in similar terms. The primary difference is wording: one outlet describes the launch of a $1.5 billion repurchase program, while the other refers to the authorization of the same $1.5 billion buyback plan. Neither summary provided here includes additional details such as timing, price limits, expected duration, or how many shares may be repurchased.
Overall, the shared emphasis is on the scale of the program—$1.5 billion—while other contextual information is not included in the supplied summaries.